BioMelbourne Network
Progressing BioIndustry
News and Opinions
2013
March
In Conversation: Douglas Hilton and Adam Bandt MP
March 7 2013. Adam Bandt is the first Australian Greens MP to win a seat in the House of Representatives at a federal election.And while the seat of Melbourne, which takes in the inner suburbs and CBD of the nation’s second largest city, is often caricatured as being the home of fixie-riding latte-swilling hipsters, there’s far more to the area than merely the cliches.Melbourne is home to the ... read more…
February
Consultation Begins On Industry Innovation Precincts
February 26 2013. The Gillard Government is embarking on a new round of consultation on Industry Innovation Precincts, one of the key initiatives announced in the $1 billion Plan for Australian Jobs.The Minister for Industry and Innovation Greg Combet said stakeholder feedback would inform the detailed design of Industry Innovation Precincts.Industry Innovation Precincts will foster collaborat... read more…
Academy awards excellence in science
February 20 2013. The Australian Academy of Science today opened applications for its 2014 round of prestigious awards, including career and early career researcher awards, travelling fellowships, research bursaries and conference support.“The Australian Academy of Science will be directing close to $300 000 towards the 2014 awards as part of its commitment to celebrate and advance Australian ... read more…
Board of Taxation report into Venture Capital released
February 20 2013. Assistant Treasurer David Bradbury has released the Board of Taxation's Review of taxation arrangements under the venture capital limited partnerships regime.The Government's response to this report was announced by the Prime Minister, the Deputy Prime Minister and Treasurer and the Minister for Industry and Innovation as part of the Venture Australia package which forms an e... read more…
Phosphagenics Further Expands Pain Portfolio
February 20 2013. Melbourne drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), has completed a pre-clinical study demonstrating that its oxycodone/TPM® technology can reduce local pain without the need to deliver oxycodone into the bloodstream. This discovery has significant commercial implications and the Company intends to commence clinical trials in Quarter 3 ... read more…
Making Eye Cells from Skin Cells to Understand Blindness
February 18 2013. Melbourne researchers are turning skin cells into eye cells to help them understand an incurable form of blindness that affects one in seven older Australians: age-related macular degeneration.
The new initiative was announced today at the launch of the National Stem Cell Foundation of Australia, a new charity that is supporting stem cell research, and informing the communit... read more…
Greens Motion to Protect Science Funding Passes Parliament
February 14 2013. The House of Representatives has supported a Greens motion, supported by the Coalition and the crossbench, calling on the Labor government to protect science and research funding in the Budget.
The motion was moved by Greens Deputy Leader and Science & Research spokesperson, Adam Bandt and seconded by Liberal Member for Higgins, Kelly O’Dwyer.
“Parliament has sent a strong ... read more…
Australia's Chief Scientist: Strategic Priorities for Research
February 14 2013. Australia’s Chief Scientist Professor Ian Chubb says a proportion of government support for research should be directed to areas of most pressing concern.
"There are many important areas of research pursued in Australia,’’ he said. "But amongst all those, we have to be sure that those that are the most pressing, the most critical for us right now, are identified and supporte... read more…
Phosphagenics Oxycodone Patch Update
February 11 2013. Melbourne drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), is preparing to re-enter the clinic with its lead transdermal TPM® oxycodone patch technology by the end of Quarter 1.The patch has been successfully refined in collaboration with European development partner tesa Labtec GmbH – a company well regarded for its opioid patch development e... read more…
Phylogica and Bio-Link Collaborate to Commercialise Anti-Inflammatory Phylomers
February 5 2013. Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has entered an agreement with Bio-Link Australia Pty. Ltd., a specialist life sciences business development company, to commercialise a family of anti-inflammatory PhylomerÒ peptides for pharmaceutical use. Under the terms of the agreement, Bio-Link will work with... read more…
